No, ivabradine should NOT be given for sinus tachycardia with preserved ejection fraction
Ivabradine is specifically indicated only for heart failure with reduced ejection fraction (LVEF ≤35%), not for preserved EF. The FDA label explicitly states that ivabradine is approved "to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%" 1.
Key Evidence Against Use in Preserved EF
The EDIFY trial directly tested ivabradine in heart failure with preserved ejection fraction (HFpEF) and found no benefit whatsoever 2. Despite achieving significant heart rate reduction (-13 bpm vs -3.5 bpm with placebo), ivabradine failed to improve:
- E/e' ratio (diastolic function)
- 6-minute walk distance
- NT-proBNP levels
- Any clinical outcomes
This negative trial definitively demonstrates that heart rate reduction alone does not improve outcomes in preserved EF, unlike in reduced EF where the SHIFT trial showed clear benefit 3, 4, 5, 6.
When Ivabradine IS Appropriate
Ivabradine has proven efficacy only in these specific scenarios:
1. Heart Failure with Reduced Ejection Fraction (HFrEF)
- LVEF ≤35%
- NYHA class II-III symptoms
- Sinus rhythm with resting HR ≥70 bpm
- Already on maximally tolerated beta-blocker (or contraindication to beta-blockers)
- On guideline-directed medical therapy for at least 4 weeks
The benefit is primarily reduction in HF hospitalizations (26% relative risk reduction), with greater effect when baseline HR >77 bpm 4.
2. Inappropriate Sinus Tachycardia (IST)
Ivabradine receives a Class IIa recommendation for symptomatic IST 7, 8. In this condition with preserved EF, ivabradine:
- Reduced daytime HR from 98.4±11.2 to 84.7±9.0 bpm 9
- Eliminated >70% of symptoms 9
- Achieved complete symptom resolution in 47% of patients 9
- Proved more effective than metoprolol for HR control 7
Critical distinction: IST is a primary sinus node disorder with inappropriate tachycardia, not simply elevated heart rate in the setting of preserved EF heart failure.
Clinical Algorithm for Your Patient
If your patient has:
Preserved EF + sinus tachycardia + heart failure symptoms → Do NOT use ivabradine 2
- Focus on treating underlying causes (hypertension, volume overload, ischemia)
- Optimize diuretics, ACE inhibitors/ARBs
- Beta-blockers remain appropriate for rate control if indicated
Preserved EF + inappropriate sinus tachycardia (IST) → Consider ivabradine 7, 8
- Must first exclude physiologic causes (anemia, hyperthyroidism, deconditioning, medications)
- Distinguish from focal atrial tachycardia (which has sudden onset/termination)
- Start 2.5-7.5 mg twice daily 7
Reduced EF (≤35%) + sinus tachycardia → Ivabradine is appropriate 3, 4, 5
- But only after maximizing beta-blocker therapy
- Start 5 mg twice daily, titrate to 7.5 mg based on HR 1
Important Caveats
- Ivabradine has no effect on blood pressure or contractility, making it well-tolerated when beta-blockers cause hypotension 4
- Requires sinus rhythm to work (blocks If current in sinus node) 4
- Increases risk of atrial fibrillation (5.0% vs 3.9% per patient-year) 1
- Can cause phosphenes (visual brightness) in 3% of patients 7
- Contraindicated in severe hepatic impairment 4, 1
Bottom line: The presence of preserved EF is a contraindication to ivabradine use for heart failure, regardless of heart rate, unless the patient has a separate diagnosis of IST as a primary arrhythmia disorder.